These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29745885)

  • 1. Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.
    Teitsma XM; Jacobs JWG; Concepcion AN; Pethö-Schramm A; Borm MEA; van Laar JM; Bijlsma JWJ; Lafeber FPJG
    Clin Exp Rheumatol; 2018; 36(6):976-983. PubMed ID: 29745885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
    Teitsma XM; Jacobs JWG; Mokry M; Borm MEA; Pethö-Schramm A; van Laar JM; Bijlsma JWJ; Lafeber FPJ
    Arthritis Res Ther; 2017 Jul; 19(1):170. PubMed ID: 28728565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
    Teitsma XM; Yang W; Jacobs JWG; Pethö-Schramm A; Borm MEA; Harms AC; Hankemeier T; van Laar JM; Bijlsma JWJ; Lafeber FPJG
    Arthritis Res Ther; 2018 Oct; 20(1):230. PubMed ID: 30322408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
    Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
    Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.
    Teitsma XM; Devenport J; Jacobs JWG; Pethö-Schramm A; Borm MEA; Budde P; Bijlsma JWJ; Lafeber FPJG
    PLoS One; 2020; 15(12):e0241189. PubMed ID: 33301475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
    Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; Hendriks L; Denissen NHAM; van Laar JM; Lafeber FPJG; Bijlsma JWJ
    Rheumatology (Oxford); 2017 Dec; 56(12):2179-2189. PubMed ID: 29029185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis.
    Verstappen M; Niemantsverdriet E; Matthijssen XME; le Cessie S; van der Helm-van Mil AHM
    Arthritis Res Ther; 2020 Nov; 22(1):276. PubMed ID: 33228814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
    Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
    Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
    Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
    Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
    Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
    Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis.
    Aguilar-Lozano L; Castillo-Ortiz JD; Vargas-Serafin C; Morales-Torres J; Sanchez-Ortiz A; Sandoval-Castro C; Padilla-Ibarra J; Hernandez-Cuevas C; Ramos-Remus C
    J Rheumatol; 2013 Jul; 40(7):1069-73. PubMed ID: 23729804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
    Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
    Trials; 2017 Apr; 18(1):161. PubMed ID: 28376912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study.
    Jones G; Wallace T; McIntosh MJ; Brockwell L; Gómez-Reino JJ; Sebba A
    J Rheumatol; 2017 Feb; 44(2):142-146. PubMed ID: 27909081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.